Say Goodbye to 'Laugh-Induced Incontinence'! Medtronic's Altaviva™ Offers New Freedom for Bladder Control

Recently, Medtronic announced that its Altaviva™ device has successfully received approval from the U.S. Food and Drug Administration (FDA). This news has instantly ignited hope among the medical community and the vast number of patients suffering from urgency urinary incontinence. Previously, patients often found themselves in a dilemma when facing treatment options—traditional treatments were either highly invasive, causing significant harm to the body, or came with various potential side effects that made patients hesitant. The emergence of the Altaviva™ device brings new hope to patients, offering them the possibility of escaping the torment of their condition.

The reason why the Altaviva™ device brings new hope to patients with urgency urinary incontinence lies in the innovative technology it employs — Implantable Tibial Nerve Modulation (ITNM) therapy. The principle behind this therapy involves the complex and sophisticated neural regulation mechanisms within our bodies. Simply put, bladder control is not just about the bladder itself; there is a close communication link between the bladder and the brain. When urgency urinary incontinence occurs, this communication link is "disrupted," causing the bladder to fail to properly receive control signals sent by the brain.

The Altaviva™ device works in a highly ingenious way. It is compact in size, with a length approximately half that of a stick of gum. During minimally invasive surgery, it can be accurately implanted near the ankle without the need for sedation or imaging technology. This location is not chosen at random; it is close to the tibial nerve. Once implanted, the device quietly "resides" just beneath the skin and above the fascia, acting like a diligent "communication soldier," sending electrical pulses to the tibial nerve. These electrical pulses are akin to little "messengers," traveling along the nerve pathways to help restore disrupted communication between the bladder and the brain. By doing so, it readjusts bladder control, allowing the bladder to follow the brain’s commands, thereby effectively alleviating symptoms of urgency urinary incontinence. To use an analogy, it’s like when our mobile phone signal is weak, we adjust the signal receiver to stabilize and improve the connection, enabling smooth calls and information reception. In this way, the Altaviva™ device helps patients regain control over their bladder, freeing them from the distress caused by urgency urinary incontinence.

The Altaviva™ device is not only innovative in its treatment principle, but also shows great advantages in the user experience it brings to patients, truly starting from the patient's perspective and bringing positive changes to their lives.

From the surgical process, patients do not need to endure long and painful operations. The Altaviva™ device adopts minimally invasive surgery, which does not require sedation, allowing patients to complete the procedure while being relatively awake. Moreover, the surgery does not rely on complex imaging techniques for positioning assistance, reducing both operation time and risks as well as alleviating psychological stress for the patient. After the surgery, patients receiving the Altaviva™ device can go home and activate the treatment later — a first in implantable tibial devices for treating urgency urinary incontinence. There is no longer a need for extended hospital observation, enabling patients to return more quickly to their familiar living environments and resume daily activities, significantly minimizing the impact on their life and work.

The Altaviva™ device is only about half the length of a stick of gum. Its compact size does not impose an excessive burden on the patient’s body. It quietly “hides” beneath the skin and above the fascia, making it nearly undetectable by others. This allows patients to appear no different from anyone else, avoiding feelings of inferiority caused by having visible medical equipment on their body. Moreover, its battery life is exceptionally long, lasting up to 15 years under expected treatment settings. This means that patients will not need to worry about battery life for an extended period and won’t have to frequently replace or perform complex maintenance on the battery. Additionally, the device automatically provides treatment without requiring daily intervention or manual adjustments from the patient. It’s like having a thoughtful little assistant silently safeguarding the patient’s health, allowing them to enjoy life with greater ease.

In terms of charging, the Altaviva™ device also performs exceptionally well. With the default charging speed, it takes no more than 30 minutes to fully charge, and there is no need for a dedicated charging device at home on a daily basis. Imagine this: during a busy day, patients can conveniently charge the device in short breaks, such as while watching TV or during lunch breaks, without disrupting their normal routine. Additionally, for patients who may require medical imaging tests, the MRI compatibility of the Altaviva™ device is undoubtedly a "reassurance." Whether it's a scheduled regular check-up or an unexpected imaging test due to sudden discomfort, patients can undergo the examination with peace of mind, without worrying about the device interfering with the results or being damaged by the procedure.

Overall, the Altaviva™ device, with its convenient surgical process and excellent equipment features, allows patients to experience unprecedented ease and comfort during the treatment of urgency urinary incontinence. It is not just a medical device, but also a beacon of hope for patients to regain a better life.

The approval of the Altaviva™ device has injected new vitality into the urinary incontinence treatment market. In the past, although there were some treatment methods, most of them had various limitations, resulting in low market penetration. With its unique advantages, such as minimally invasive, convenience, and high efficiency, the Altaviva™ device is expected to attract more patients to choose it for treatment, thereby changing the competitive landscape of the market. As the developer of this device, Medtronic will further consolidate its leading position in the field of neuromodulation with this innovative product. Previously, Medtronic already had a rich product line and deep technical accumulation in the field of neuromodulation. The launch of the Altaviva™ deviceMaking it the only company with a complete neuromodulation therapy portfolio for urgency urinary incontinence., which will undoubtedly enhance Medtronic's competitiveness in the market, attracting more medical resources and market share to lean towards it.

From the perspective of technological development, the approval of the Altaviva™ device marks a new starting point. It will drive the entire neuromodulation technology towards more precise, intelligent, and convenient directions. Other medical companies will also be motivated to increase R&D investment in related fields, fostering a positive atmosphere of innovation within the industry. In the future, we may expect more similar innovative products to emerge, continuously optimizing treatment options and providing patients with more and better choices. For example, there may be breakthroughs in electrode materials and design, enabling electrical stimulation to target nerves more accurately. In terms of device intelligence, real-time interaction with the patient’s physical condition may be achieved, automatically adjusting treatment parameters based on the patient's specific needs.

Looking Ahead to Medtronic's Development Prospects in the Field of Neuromodulation

This Issue's Planning: Shen Li

Editorial Responsibility: Chen Baolin

Author of this article: Yun Ye Xuan

Post-production: Zhang Lirong